1 |
ClinicalTrials.gov (NCT02465983) Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer
|
2 |
2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
|
3 |
2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
|
4 |
Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
|
5 |
Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
|
6 |
Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
|
7 |
Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
|
8 |
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645.
|
9 |
Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag. 2021 Jan 14;17:39-54.
|
10 |
A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60.
|
11 |
ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL
|
12 |
Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015 Apr 20;33(12):1325-33.
|
13 |
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 1;20(23):5927-36.
|
14 |
ClinicalTrials.gov (NCT01583686) CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
|
15 |
ClinicalTrials.gov (NCT03545815) Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.
|
16 |
ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer
|
17 |
ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
|
18 |
Clinical pipeline report, company report or official report of Harpoon Therapeutics.
|
19 |
ClinicalTrials.gov (NCT02959151) A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
|
20 |
Clinical pipeline report, company report or official report of TCR2 Therapeutics.
|
21 |
Clinical pipeline report, company report or official report of TCR2 Therapeutics
|
|
|
|
|
|
|